Clinical Trial Update: A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) [Phase 3]

View source ↗

Summary

A Phase 3 multicenter trial comparing IBI343 monotherapy to placebo in previously treated CLDN18.2-positive pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• IBI343

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Pancreatic Cancer | Phase 3 | Status: RECRUITING